UM  > 中華醫藥研究院
Engineering a vascular endothelial growth factor 165-binding heparan sulfate for vascular therapy
Wang C.1; Poon S.1; Murali S.1; Koo C.-Y.1; Bell T.J.2; Hinkley S.F.2; Yeong H.2; Bhakoo K.3; Nurcombe V.1,4; Cool S.M.1,5
2014
Source PublicationBiomaterials
ISSN1429612
Volume35Issue:25Pages:6776
Abstract

The therapeutic use of VEGF165 to stimulate blood vessel formation for the treatment of peripheral arterial disease or cardiovascular-related disease has met with limited success. Here we describe an affinity-isolated heparan sulfate glycotherapeutic (HS7+ve) that binds to, and enhances the bioactivity of, VEGF165. Application of HS7+ve complexed with VEGF165 results in enhanced VEGF165-VEGFR2 interaction, prolonged downstream pErk1/2 signalling, and increased cell proliferation and tube formation in HUVECs, compared with VEGF165 alone. The pro-angiogenic potential of HS7+ve was further assessed invivo using the chick embryo chorioallantoic membrane (CAM) assay. Exogenous dosing with HS7+ve alone significantly enhanced the formation of new blood vessels with potencies comparable to VEGF165. These results demonstrate the potential for vascular therapy of glycotherapeutic agents targeted at augmenting the bioactivity of VEGF165. © 2014 Elsevier Ltd.

KeywordAngiogenesis Blood Vessel Glycosaminoglycans Heparin Vasculogenesis Vegf
DOI10.1016/j.biomaterials.2014.04.084
URLView the original
Indexed BySCI
Language英语
WOS Research AreaEngineering ; Materials Science
WOS SubjectEngineering, Biomedical ; Materials Science, bioMaterials
WOS IDWOS:000338386800011
The Source to ArticleScopus
Fulltext Access
Citation statistics
Cited Times [WOS]:31   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionInstitute of Chinese Medical Sciences
Affiliation1.Glycotherapeutics Group, Institute of Medical Biology, Agency for Science, Technology and Research, Singapore
2.The Ferrier Research Institute, Victoria University of Wellington, Lower Hutt, New Zealand
3.Translational Molecular Imaging Group, Singapore Bioimaging Consortium, Agency for Science, Technology and Research, Singapore
4.Lee Kong Chian School of Medicine, Nanyang Technological University–Imperial College London, Singapore
5.Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Recommended Citation
GB/T 7714
Wang C.,Poon S.,Murali S.,et al. Engineering a vascular endothelial growth factor 165-binding heparan sulfate for vascular therapy[J]. Biomaterials,2014,35(25):6776.
APA Wang C..,Poon S..,Murali S..,Koo C.-Y..,Bell T.J..,...&Cool S.M..(2014).Engineering a vascular endothelial growth factor 165-binding heparan sulfate for vascular therapy.Biomaterials,35(25),6776.
MLA Wang C.,et al."Engineering a vascular endothelial growth factor 165-binding heparan sulfate for vascular therapy".Biomaterials 35.25(2014):6776.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Wang C.]'s Articles
[Poon S.]'s Articles
[Murali S.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Wang C.]'s Articles
[Poon S.]'s Articles
[Murali S.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Wang C.]'s Articles
[Poon S.]'s Articles
[Murali S.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.